Cannabis Use During Pregnancy Linked to Increased Cardiovascular Disease Risk in Offspring, Study Suggests
A study published in *JAMA Pediatrics* in 2023 found a potential association between maternal cannabis use during pregnancy and an elevated risk of cardiovascular disease (CVD) in offspring, according to research conducted by the Kaiser Permanente Division of Research. The analysis, which followed over 11,000 mother-child pairs, reported that children exposed to cannabis in utero had a 20% higher risk of developing CVD compared to those without prenatal exposure.
Study Methodology and Key Findings
The study, led by Dr. Marcella Perales, utilized electronic health records from Kaiser Permanente Northern California to track outcomes in children born between 2000 and 2015. Researchers defined cannabis exposure as any use of tetrahydrocannabinol (THC) during pregnancy, regardless of frequency. Over a 15-year follow-up period, 4.2% of children with prenatal cannabis exposure developed CVD, compared to 3.5% in the unexposed group.
The findings align with earlier research suggesting that endocrine and metabolic disruptions from cannabis may affect fetal development. However, the study’s authors emphasized that correlation does not prove causation, noting that confounding factors—such as socioeconomic status or co-occurring substance use—could influence the results.
Expert Perspectives on the Research
Dr. Sarah Kim, a maternal-fetal medicine specialist at the University of Washington, noted that while the study adds to growing concerns about cannabis use during pregnancy, more research is needed to establish a direct causal link. “The data is preliminary, but it underscores the importance of caution,” she said. “Pregnant individuals should consult healthcare providers before using cannabis, even if it’s for medical purposes.”
The American College of Obstetricians and Gynecologists (ACOG) reiterated its recommendation against cannabis use during pregnancy, citing potential risks to fetal growth and neurodevelopment. ACOG spokesperson Dr. Lisa Hollier stated, “There is no safe level of cannabis exposure during pregnancy. This study reinforces that message.”
Implications for Public Health
As cannabis legalization expands across the U.S., the study highlights the need for clearer guidelines. The Centers for Disease Control and Prevention (CDC) advises against cannabis use during pregnancy, emphasizing that “no amount of cannabis is known to be safe for the developing fetus.”
Public health officials also stress the importance of education. “Many individuals may not realize that cannabis can cross the placenta and affect the baby’s health,” said Dr. Michael Smith, a CDC epidemiologist. “We need targeted messaging to ensure pregnant people are informed about the risks.”
Limitations and Future Research
The study’s authors acknowledged several limitations, including reliance on self-reported cannabis use and the inability to account for all environmental factors. Additionally, the majority of participants were non-Hispanic white, raising questions about the findings’ generalizability.
Further research is needed to explore mechanisms linking cannabis exposure to CVD, as well as to assess long-term outcomes in exposed children. The National Institutes of Health (NIH) has funded additional studies to investigate these questions, with results expected in the next five years.
What This Means for Pregnant Individuals
Healthcare providers recommend that pregnant individuals avoid cannabis use, particularly in the first trimester, when organ development is most vulnerable. For those using cannabis for medical reasons, alternatives such as non-cannabinoid treatments should be discussed with a physician.
“We’re still learning about the full impact of cannabis on pregnancy,” said Dr. Perales. “But the evidence so far suggests that avoiding it is the safest choice.”
Conclusion
While the link between prenatal cannabis exposure and cardiovascular disease remains under investigation, the study contributes to a growing body of research warning against its use during pregnancy. As policies evolve, healthcare professionals and public health agencies continue to prioritize patient education and risk mitigation.
Related reading